Compare CRBU & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRBU | ENLV |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.6M | 149.0M |
| IPO Year | 2021 | 2014 |
| Metric | CRBU | ENLV |
|---|---|---|
| Price | $1.59 | $4.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $10.75 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.4M | 280.7K |
| Earning Date | 05-08-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.63 | N/A |
| Revenue Next Year | $10.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.38 | $0.43 |
| 52 Week High | $3.53 | $7.64 |
| Indicator | CRBU | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 35.14 | 57.84 |
| Support Level | $1.39 | $0.79 |
| Resistance Level | $1.73 | $7.64 |
| Average True Range (ATR) | 0.11 | 0.59 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 0.94 | 50.64 |
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.